Session: SUN 758-779-Cardiometabolic Risk & Vascular Biology
Poster Board SUN-767
Aim of the study : To investigate any possible relationship between RAGE polymorphisms with CHD and the association of RAGE polymorphisms with cardiovascular risk factors in postmenopausal women.
Methods: 96 menopausal women (28 diabetics - 68 non diabetics, mean age: 68,34yrs) who underwent coronary angiography were genotyped for the -429T/C and -374T/A variants of RAGE. In this group androgen and estrogen levels, lipid parameters, glucose, HbA1c and insulin were determined and Free Androgen Index was calculated.
Results: Τhere was no significant difference in RAGE polymorphisms frequencies between women with CHD confirmed in coronary angiography and those without CHD, although a cardioprotective trend was disclosed for 374AA polymorhism. Regarding hormonal/metabolic profile, women with homozygosity for the -429 allele (TT) had significantly lower levels of HDL (43,7 ± 17,16 vs. 52,95 ± 14,47, P=0.036) and SHBG (42,73 ± 18,17 vs 52,55 ± 20,71, P=0.038) compared to eterozygotic subjects (TC) and significantly higher levels of triglycerides (151,75 ± 50,65 vs. 125,89 ± 36,64, P=0.042), FAI (1,85 ± 1,43 vs. 1,17 ± 0,84, P=0.042) and Androstenedione (1,61 ± 1,01 vs. 1,22± 0,58, P=0.031). Women with homozygosity for the -374 allele (AA) had significantly lower LDL levels (83,8 ± 21,96 vs 105 ± 42,97, P=0.046) compared to eterozygotic (AT) subjects.
Conclusion: Our data did not demonstrate an association between polymorphisms of the RAGE gene and CHD in menopausal women. However, homozygosity for the -429 allele (TT) of RAGE is associated with an adverse lipid profile and hyperandrogenemia and its role as a predisposing factor of atherosclerosis needs further evaluation.
Nothing to Disclose: XX, SL, AK, EM, CC, CP, PK, NG, ED
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters